TETRABENAZINE METHANESULFONATE

Details

Stereochemistry	RACEMIC
Molecular Formula	C19H27NO3.CH4O3S
Molecular Weight	413.528
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of TETRABENAZINE METHANESULFONATE

Structure Search

SMILES

CS(O)(=O)=O.[H][C@@]12CC(=O)[C@@H](CC(C)C)CN1CCC3=CC(OC)=C(OC)C=C23

InChI

InChIKey=RHDADYXNUCMTQG-DMLYUBSXSA-N

InChI=1S/C19H27NO3.CH4O3S/c1-12(2)7-14-11-20-6-5-13-8-18(22-3)19(23-4)9-15(13)16(20)10-17(14)21;1-5(2,3)4/h8-9,12,14,16H,5-7,10-11H2,1-4H3;1H3,(H,2,3,4)/t14-,16-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C19H27NO3
Molecular Weight	317.4226
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	CH4O3S
Molecular Weight	96.106
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21396745https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/xenazine-tetrabenazine-343075 | https://www.drugbank.ca/drugs/DB04844 | https://www.drugs.com/cdi/tetrabenazine.html

Tetrabenazine (trade name Xenazine) is a monoamine depleter and used as the symptomatic treatment of chorea associated with Huntington's disease. Tetrabenazine is a reversible human vesicular monoamine transporter type 2 inhibitor (Ki = 100 nM). It acts within the basal ganglia and promotes depletion of monoamine neurotransmitters serotonin, norepinephrine, and dopamine from stores. It also decreases uptake into synaptic vesicles. Dopamine is required for fine motor movement, so the inhibition of its transmission is efficacious for hyperkinetic movement. Tetrabenazine exhibits weak in vitro binding affinity at the dopamine D2 receptor. The most common adverse reactions, which have occurred in at least 10% of subjects in studies and at least 5% greater than in subjects who received placebo, have been: sedation or somnolence, fatigue, insomnia, depression, suicidal thoughts, akathisia, anxiety, and nausea.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Synaptic vesicular amine transporter 53 Target ID: CHEMBL1893 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21396745	Inhibitor 8146		36.4 µM [Ki]
Synaptic vesicular amine transporter 53 Target ID: CHEMBL1893 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21396745	Inhibitor 8146		54.0 nM [Ki]

Conditions

Condition	Modality	Highest Phase	Product
Huntington's disease 24 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	Primary	Approved 8307	XENAZINE Approved Use Tetrabenazine tablets are indicated for the treatment of chorea associated with Huntington's disease. Tetrabenazine tablets are a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington's disease. (1) Launch Date 1.21875844E12
Tardive dyskinesia 15 Sources: https://clinicaltrials.gov/ct2/show/NCT01543321	Primary	Phase III 651	XENAZINE Approved Use Tetrabenazine tablets are indicated for the treatment of chorea associated with Huntington's disease. Tetrabenazine tablets are a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington's disease. (1) Launch Date 1.21875844E12
Tourette's syndrome 20 Sources: https://clinicaltrials.gov/ct2/show/NCT01133353	Primary	Phase II 1133	XENAZINE Approved Use Tetrabenazine tablets are indicated for the treatment of chorea associated with Huntington's disease. Tetrabenazine tablets are a vesicular monoamine transporter 2 (VMAT) inhibitor indicated for the treatment of chorea associated with Huntington's disease. (1) Launch Date 1.21875844E12
Unknown 2554

C_max

Value	Dose	Co-administered	Analyte	Population
1.66 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23339053	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		TETRABENAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
3.45 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23339053	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		TETRABENAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.13 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23339053	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		TETRABENAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
14% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23339053	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		TETRABENAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	Other AEs: Acute dystonia, Crisis oculogyric... Other AEs: Acute dystonia Crisis oculogyric Nausea and vomiting Sweating Sedation Hypotension Confusion Diarrhea Hallucinations Redness Tremor Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
12.5 mg 1 times / day steady, oral (starting) Recommended Dose: 12.5 mg, 1 times / day Route: oral Route: steady Dose: 12.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: Huntington’s disease Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	Other AEs: Depression, Suicidal tendency... Other AEs: Depression Suicidal tendency Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf

AEs

AE	Dose	Population
Acute dystonia	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Confusion	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Crisis oculogyric	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Diarrhea	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Hallucinations	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Hypotension	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Nausea and vomiting	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Redness	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Sedation	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Sweating	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Tremor	1 g single, oral Overdose Dose: 1 g Route: oral Route: single Dose: 1 g Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unknown, adult n = 8 Health Status: unknown Age Group: adult Population Size: 8 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Depression	12.5 mg 1 times / day steady, oral (starting) Recommended Dose: 12.5 mg, 1 times / day Route: oral Route: steady Dose: 12.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: Huntington’s disease Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf
Suicidal tendency	12.5 mg 1 times / day steady, oral (starting) Recommended Dose: 12.5 mg, 1 times / day Route: oral Route: steady Dose: 12.5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: Huntington’s disease Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021894lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inducer 753	inducer 372 inhibitor 1695 substrate 985	inhibitor 1789 substrate 1168

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 1463 CYP2B6 770 CYP2C19 1410 CYP2C8 869 CYP2E1 846 CYP3A 208 P-gp 1401	CYP1A2 1013 P-gp 1491 CYP2C19 955 CYP2B6 648	CYP1A2 671 CYP2B6 521 CYP2C19 283 CYP2C8 163

Drug as perpetrator

Target	Modality	Activity
CYP2B6 946	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	inconclusive
CYP1A2 1620	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
CYP1A2 1620	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
CYP2B6 946	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
CYP2C19 1484	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
CYP2C19 1484	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
CYP2C8 923	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
CYP2C8 923	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
CYP2C9 1747	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
CYP2C9 1747	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
CYP2D6 1826	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 66, 67, 79	no
CYP2E1 929	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
CYP3A 291	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
CYP3A4 1857	inducer 1515 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 67, 79	no
P-gp 1588	inhibitor 3185 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 80.0	no

Drug as victim

Target	Modality	Activity	Clinical evidence
CYP2B6 648	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 77.0	inconclusive
CYP2C19 955	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 76.0	inconclusive
CYP2C9 985	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 76.0	inconclusive
P-gp 1491	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 80.0	no	no (co-administration study) Comment: tetrabenazine did not affect bioavailability of digoxin Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 80.0
CYP1A2 1013	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 76.0	yes
CYP2D6 1168	substrate 3264 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/021894s000_ClinPharmR_P1.pdf Page: 14, 65, 76	yes

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY102209
1PlusChem LLC	1P003V33
AChemBlock	G-6717
AChemBlock	G-6719
AK Scientific	SYN5556
AK Scientific	Z3433
AbovChem LLC	HY-B0590
AbovChem LLC	HY-B0590A
Angene	AGN-PC-0TZHQ7
ApexBio Technology	B3542
AstaTech	51348
BLD Pharm	BD160994
BLD Pharm	BD261817
BOC Sciences	58-46-8
BioBlocks	A2708/0115225
BioBlocks	ZERO/009651
BioSynth	Q-101507
BlocksMatrix Scientific	113473
Capot Chemical	26005
Capot Chemical	26006
Cayman Chemical	20380
Chem Scene	CS-2801
Chem Scene	CS-5700
ChemDiv	8012-5225
ChemDiv	BB54-4011
ChemShuttle	153274
Combi-Blocks	QA-3894
Compound Cloud	6018
Enamine	EN300-122639
Excenen	EX-A2361
Fluorochem	301460
Fluorochem	329781
Hairui	HR104170
Hangzhou Yuhao Chemical Technology	RT15427
KeyOrganics	AS-16884
KeyOrganics	AS-35785
Lab Network	LN00215056
Lab Seeker	SC-20416
Lan Pharmatech	LQT-B48322
MedChem Express	HY-B0590
MedChem Express	HY-B0590A
MolPort	MolPort-002-712-672
MolPort	MolPort-008-266-772
MolPort	MolPort-044-813-606
MolPort	MolPort-046-417-356
MolPort	MolPort-046-785-843
Molcore	MC102209
Molcore	MC103880
Molcore	MC103881
Molnova	M15145
Molnova	M19033
MuseChem	A000815
MuseChem	I012177
NCI Plated 2007	169886
NCI Plated 2007	172187
Norris Pharm	NSZB-A278881
Princeton BioMolecular Research	OSSL_637198
Ryan Scientific	Clinafloxacin
Selleck Chemicals	S1789
ShangHai Biochempartner	BCP24156
StruChem	SC-20416
Synthonix	12157
TargetMol	T0719
TargetMol	T3534
Tetrahedron	TS88404
TimTec	SBB018797
TimTec	ST028814
Tocris	2175
Toronto Research Chemicals	T284000
Toronto Research Chemicals	T284023
Toronto Research Chemicals	T889552
Vitas-M Laboratory	STK678061
W&J PharmaChem	50C801141
ZINC	ZINC000003875393	http://zinc15.docking.org/substances/ZINC000003875393
Zelinsky Institute	UZI/2617073
eMolecules	2578999
eMolecules	275978188
eMolecules	8318622
eNovation Chemicals	D500323
mcule	MCULE-4590614455
mcule	MCULE-5458437044
mcule	MCULE-5822627411
mcule	MCULE-6472043806

PubMed

Title	Date	PubMed
[Behavior pharmacology of maprotiline, a new antidepressant].	1975 Nov	1240830
Adenosine release in morphine-induced hypotension in rats.	1992 Jan	1592228
Modulation of gastrin processing by vesicular monoamine transporter type 1 (VMAT1) in rat gastrin cells.	1999 Jun 1	10332097
Pharmacological options for the treatment of Tourette's disorder.	2001	11772131
Interactions of 1-methyl-4-phenylpyridinium and other compounds with P-glycoprotein: relevance to toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.	2001 Aug 10	11489261
Hemichorea, moya-moya, and ulcerative colitis.	2001 May	11391762
Structure-activity studies leading to (-)1-(benzofuran-2-yl)-2-propylaminopentane, ((-)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.	2001 May	11377178
Dyskinesia: L-dopa-induced and tardive dyskinesia.	2001 Nov-Dec	11801806
Assessing the integrity of the dopamine system in Parkinson's disease: how best to do it?	2001 Sep	11746608
Hemiballismus.	2002 Apr	12090446
Increased platelet vesicular monoamine transporter density in adult schizophrenia patients.	2002 Aug	12126874
Evaluation of the central properties of several Hypericum species from the Canary Islands.	2002 Dec	12458477
Human megakaryocytes cultured in vitro accumulate serotonin but not meta-iodobenzylguanidine whereas platelets concentrate both.	2002 Jun	12063022
Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2.	2002 Jun	12007678
Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.	2002 Mar	11861820
Elevated platelet vesicular monoamine transporter density in untreated patients diagnosed with major depression.	2002 Nov 15	12450634
Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.	2002 Oct 1	12351745
Catastrophic reactions induced by tetrabenazine.	2002 Sep	12355681
Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice.	2002 Sep	12213134
1-(Benzofuran-2-yl)-2-(3,3,3-trifluoropropyl)aminopentane HCl, 3-F-BPAP, antagonizes the enhancer effect of (-)-BPAP in the shuttle box and leaves the effect of (-)-deprenyl unchanged.	2002 Sep 13	12175892
Increased ventral striatal monoaminergic innervation in Tourette syndrome.	2003 Aug 12	12913189
Self-biting induced by activation of L-type calcium channels in mice: dopaminergic influences.	2003 Jan-Feb	12876427
Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA.	2003 Jul 8	12847153
REM sleep behavior disorder is related to striatal monoaminergic deficit in MSA.	2003 Jul 8	12847152
Gilles de la Tourette's syndrome.	2003 Mar	12691479
Decreased limbic vesicular monoamine transporter 2 in a genetic rat model of depression.	2003 Mar 7	12591135
Dopamine transmission in DYT1 dystonia.	2004	14509654
Adrafinil-induced orofacial dyskinesia.	2004 Aug	15300665
[Movement disorders in childhood: therapeutic update].	2004 Aug	15288089
Electrochemical monitoring of transport by a vesicular monoamine transporter expressed in Xenopus oocytes.	2004 Feb 15	14757360
Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys.	2004 Jul	15039771
Identification of tissue-restricted transcripts in human islets.	2004 Oct	15231694
The influence of measurement uncertainties on the evaluation of the distribution volume ratio and binding potential in rat studies on a microPET R4: a phantom study.	2005 Jun 21	15930607
Decreased platelet vesicular monoamine transporter density in children and adolescents with attention deficit/hyperactivity disorder.	2005 Mar	15695060
Pharmacological management of Huntington's disease: an evidence-based review.	2006	16842168
Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series.	2006 Feb 28	16507108
Tetrabenazine versus placebo for chorea in Huntington's disease.	2006 Jul	16858878
Longitudinal noninvasive PET-based beta cell mass estimates in a spontaneous diabetes rat model.	2006 Jun	16710474
Huntington's Disease.	2006 May	16569382
Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors.	2011 May	21396745

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 17 02:06:18 UTC 2022` Edited by `admin` on `Sat Dec 17 02:06:18 UTC 2022`
Record UNII	5X57I1N37U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TETRABENAZINE METHANESULFONATE

Common Name

English

TETRABENAZINE MESYLATE

Common Name

English

(3R,11BR)-REL-1,3,4,6,7,11B-HEXAHYDRO-9,10-DIMETHOXY-3-(2-METHYLPROPYL)-2H-BENZO(A)QUINOLIZIN-2-ONE METHANESULFONATE

Common Name

English

(3R,11BR)-REL-1,3,4,6,7,11B-HEXAHYDRO-9,10-DIMETHOXY-3-(2-METHYLPROPYL)-2H-BENZO(A)QUINOLIZIN-2-ONE METHANESULPHONATE

Common Name

English

TETRABENAZINE MESILATE

Common Name

English

TETRABENAZINE METHANESULPHONATE

Common Name

English

TETRABENAZINE METHANESULFONATE [MI]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C471